Publications by authors named "Yevgeniya A Byekova"

Objective: To demonstrate the clinical efficacy of topical 5% imiquimod for mycosis fungoides (MF) tumors.

Background: Treatment of tumor-stage MF represents a therapeutic challenge because of a limited number of effective topical therapies. Single tumors can be treated with localized radiation but may recur.

View Article and Find Full Text PDF

LKB1, a known tumor suppressor, is mutated in Peutz-Jeghers Syndrome (PJS). It is responsible for the enhanced cancer risk in patients with PJS. Dysregulation of LKB1-dependent signaling also occurs in various epithelial cancers.

View Article and Find Full Text PDF

Entamoeba histolytica is an intestinal protozoan parasite that causes amoebic dysentery and liver abscess. Phagocytosis by the parasite is a critical virulence process, since it is a prerequisite for tissue invasion and establishment of chronic infection. While the roles of many of the proteins that regulate phagocytosis-related signaling events in E.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Yevgeniya A Byekova"

  • - Yevgeniya A Byekova’s research primarily focuses on skin-related disorders and the efficacy of different treatment modalities, particularly in the context of mycosis fungoides and other dermatological conditions.
  • - A significant finding includes the demonstration of the clinical efficacy of topical 5% imiquimod cream for the complete resolution of mycosis fungoides tumors, addressing a therapeutic challenge in tumor-stage cases.
  • - Byekova's studies also delve into the molecular mechanisms underlying cancer pathogenesis, such as the role of liver kinase B1 (LKB1) in ultraviolet B (UVB)-induced basal cell carcinoma, indicating its involvement in various epithelial cancers.